Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must understand and voluntarily sign an informed consent form~* Age 18 years at the time of signing the informed consent form~* Documented diagnosis of myelodysplastic syndromes (MDS) that meets International Prognostic Scoring System (IPSS) criteria for low to intermediate-1-risk disease and has an associated del 5q(31) cytogenetic abnormality~* Red blood cell (RBC) transfusion dependent anaemia defined as not having any 56 days without a RBC transfusion within at least the immediate 112 days~* Must be able to adhere to the study visit schedule and other protocol requirements~* Women of childbearing potential must have a negative pregnancy test prior to inclusion~Exclusion Criteria:~* Pregnant or lactating females~* Prior therapy with lenalidomide~* Proliferative (white blood cell (WBC)= 12,000/mL) chronic myelomonocytic leukemia (CMML)~* Prior \>= grade-2 (using the National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) (v 3.0)) allergic reaction to thalidomide~* Prior desquamating (blistering) rash while taking thalidomide~* Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for \>3 years~* Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days~* Less than 6 months since prior allogeneic bone marrow transplantation~* Less than 3 months since prior autologous bone marrow or stem cell transplantation~* Less than 28 days since prior myelosuppressive anticancer biologic therapy~* Recombinant human erythropoietin (rHuEPO) therapy received within 28 days~* Known human immunodeficiency virus (HIV-1) positivity~* Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he or she participates in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching to active study arms.
- Lenalidomide 5 mg (Type: EXPERIMENTAL): Lenalidomide 5 mg daily 28/28 days
- Lenalidomide 10 mg (Type: EXPERIMENTAL): Lenalidomide 10 mg daily 21/28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).